-
scientist who is the
founder and
former CEO of the
pharmaceutical company Exscientia,
which develops drugs using artificial intelligence. He was
educated at...
- 2019-09-11. "Professor
Charlotte Deane Joins Exscientia as
Chief Scientist of
Biologics AI".
Exscientia. 2022-01-19.
Retrieved 2022-01-27. "No. 63714"...
- In
August 2024, the
company acquired UK-based
biotechnology company Exscientia for $688 million. By 2015,
Recursion had
closed its
Series A
round of...
-
Europe June 2020
NodThera Venture Investments North America May 2020
Exscientia Growth Investments Europe April 2020
Biomason Planetary Health Investments...
-
inhibitor that is
potentially first-in-class medication.
Developed by
Exscientia, it was
licensed to
Bristol Myers Squibb. In 2023, it
entered clinical...
-
occupiers at
Milton Park
include but are not
limited to:
Adaptimmune Evotec Exscientia Immunocore Tokamak Energy New
England Biolabs Nexeon OBN
Oxitec RM Taylor...
- Philippidis, Alex (1
January 2023). "BMS
Collaboration Paying Off for
Exscientia: AI drug
developer designs EXS4318, the I&I
small molecule that has entered...
-
Professor Andrew Lee Hopkins, FRS, FMedSci, FRSE.
Chief Executive Officer,
Exscientia. For
services to
Science and to Innovation.
Christian Edward Johnston...
-
guide to Scotland". New Scientist.
Retrieved 28
November 2018. "
Exscientia Ltd".
Exscientia Ltd.
Retrieved 4
December 2018. "Home |
Glencoe Software, Inc"...
-
human material,
which became part of the AI-driven
pharmatech company Exscientia in 2021. In 2020 he co-founded
Proxygen GmbH to
develop molecular glue...
